All In Biotech

Drug Trial Radar · NCT03891862

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Apr 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

Mar 18, 2019

Primary completion

Dec 23, 2019

Study completion Jan 30, 2020

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Mar 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.

Conditions

  • Tardive Dyskinesia (TD)

Interventions

  • ValbenazineDrug

    vesicular monoamine transporter 2 (VMAT2) inhibitor

  • Placebo oral capsuleDrug

    non-active dosage form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Randomization (Week 8) in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 16Time frame: Week 8, Week 16

Locations

43 sites in 2 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Little Rock, Arkansas

  • Neurocrine Clinical Site

    Anaheim, California

  • Neurocrine Clinical Site

    Anaheim, California

  • Neurocrine Clinical Site

    Costa Mesa, California

  • Neurocrine Clinical Site

    Escondido, California

  • Neurocrine Clinical Site

    Fountain Valley, California

  • Neurocrine Clinical Site

    Glendale, California

  • Neurocrine Clinical Site

    La Habra, California

  • Neurocrine Clinical Site

    Lemon Grove, California

  • Neurocrine Clinical Site

    Norwalk, California

  • Neurocrine Clinical Site

    San Bernardino, California

  • Neurocrine Clinical Site

    San Diego, California

  • Neurocrine Clinical Site

    Torrance, California

  • Neurocrine Clinical Site

    Pueblo, Colorado

  • Neurocrine Clinical Site

    Hialeah, Florida

  • Neurocrine Clinical Site

    Hialeah, Florida

  • Neurocrine Clinical Site

    Hialeah, Florida

  • Neurocrine Clinical Site

    Miami, Florida

  • Neurocrine Clinical Site

    North Miami, Florida

  • Neurocrine Clinical Site

    Orlando, Florida

  • Neurocrine Clinical Site

    South Bend, Indiana

  • Neurocrine Clinical Site

    Bloomfield Hills, Michigan

  • Neurocrine Clinical Site

    East Lansing, Michigan

  • Neurocrine Clinical Site

    Grand Rapids, Michigan

  • Neurocrine Clinical Site

    Kansas City, Missouri

  • Neurocrine Clinical Site

    St Louis, Missouri

  • Neurocrine Clinical Site

    Lincoln, Nebraska

  • Neurocrine Clinical Site

    Las Vegas, Nevada

  • Neurocrine Clinical Site

    New York, New York

  • Neurocrine Clinical Site

    Beachwood, Ohio

  • Neurocrine Clinical Site

    Mason, Ohio

  • Neurocrine Clinical Site

    Oklahoma City, Oklahoma

  • Neurocrine Clinical Site

    Conshohocken, Pennsylvania

  • Neurocrine Clinical Site

    Scranton, Pennsylvania

  • Neurocrine Clinical Site

    Franklin, Tennessee

  • Neurocrine Clinical Site

    DeSoto, Texas

  • Neurocrine Clinical Site

    Houston, Texas

  • Neurocrine Clinical Site

    Houston, Texas

  • Neurocrine Clinical Site

    Irving, Texas

  • Neurocrine Clinical Site

    Richmond, Texas

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.